ethyl 2-(bis(benzyloxy)phosphoryl)-2-diazoacetate | 1357486-88-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: ethyl 2-(bis(benzyloxy)phosphoryl)-2-diazoacetate
• 英文别名: ethyl dibenzylphosphonodiazoacetate；ethyl (2E)-2-bis(phenylmethoxy)phosphoryl-2-diazoacetate
• CAS: 1357486-88-4
• 化学式: C₁₈H₁₉N₂O₅P
• 分子量: 374.333
• InChiKey: AREKYMGNZIRBOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ((3aR,4R,6R,6aR)-6-(2,6-dichloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 、 ethyl 2-(bis(benzyloxy)phosphoryl)-2-diazoacetate 在 dirhodium tetraacetate 作用下， 以 苯 为溶剂， 反应 16.0h， 以2.95 g的产率得到ethyl 2-(bis(benzyloxy)phosphoryl)-2-(((3aR,4R,6R,6aR)-6-(2,6-dichloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)acetate
  参考文献：
  名称：

  [EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER

  摘要：

  提供的是新颖化合物、其药学上可接受的盐以及其药物组合物，这些化合物是CD73的抑制剂，并可用于癌症治疗。

  公开号：

  WO2015164573A1
• 作为产物：
  描述：

  ethyl dibenzylphosphonoacetate 在 potassium tert-butylate 、 2-naphthalenesulphonyl azide 作用下， 以 甲苯 为溶剂， 反应 0.42h， 以66%的产率得到ethyl 2-(bis(benzyloxy)phosphoryl)-2-diazoacetate
  参考文献：
  名称：

  Development of O–H insertion for the attachment of phosphonates to nucleosides; synthesis of α-carboxy phosphononucleosides

  摘要：

  Development of rhodium catalysed O-H insertion reactions employing alpha-diazophosphonates with appropriately protected adenosine, uridine and thymidine derivatives is described. This synthetic methodology leads, following deprotection, to novel phosphononucleoside derivatives bearing a carboxylic acid moiety adjacent to the phosphonate. Protection strategies are critical to the success of the key O-H insertion. There are two important aspects: avoiding competing insertion pathways or catalyst poisoning, and being able to achieve deprotection without degradation of the phosphononucleosides. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.12.077

文献信息

• Purine derivatives as CD73 inhibitors for the treatment of cancer
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：US10654884B2

  公开（公告）日：2020-05-19

  Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

  本文提供了新型嘌呤核苷/核苷酸类似物化合物、其药学上可接受的盐及其药物组合物，它们是 CD73 的抑制剂，可用于治疗癌症。
• PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP3134411A1

  公开（公告）日：2017-03-01
• [EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2015164573A1

  公开（公告）日：2015-10-29

  Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

  提供的是新颖化合物、其药学上可接受的盐以及其药物组合物，这些化合物是CD73的抑制剂，并可用于癌症治疗。
• Development of O–H insertion for the attachment of phosphonates to nucleosides; synthesis of α-carboxy phosphononucleosides
  作者：Isabelle Hladezuk、Veronique Chastagner、Stuart G. Collins、Stephen J. Plunkett、Alan Ford、Sebastien Debarge、Anita R. Maguire

  DOI：10.1016/j.tet.2011.12.077

  日期：2012.2

  Development of rhodium catalysed O-H insertion reactions employing alpha-diazophosphonates with appropriately protected adenosine, uridine and thymidine derivatives is described. This synthetic methodology leads, following deprotection, to novel phosphononucleoside derivatives bearing a carboxylic acid moiety adjacent to the phosphonate. Protection strategies are critical to the success of the key O-H insertion. There are two important aspects: avoiding competing insertion pathways or catalyst poisoning, and being able to achieve deprotection without degradation of the phosphononucleosides. (C) 2012 Elsevier Ltd. All rights reserved.